TGF	O
-	O
beta1	O
reduces	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
expression	O
in	O
podocytes	O
.	O


BACKGROUND	O
:	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	O
)	O
is	O
essential	O
for	O
normal	O
podocyte	O
function	O
,	O
and	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
contributes	O
to	O
focal	B-DISEASE
segmental	I-DISEASE
glomerulosclerosis	E-DISEASE
(	O
FSGS	S-DISEASE
)	O
.	O


We	O
aimed	O
to	O
address	O
whether	O
TGF	O
-	O
beta	O
affects	O
WT1	O
expression	O
in	O
podocytes	O
.	O


METHODS	O
:	O
A	O
human	O
podocyte	O
cell	O
line	O
treated	O
with	O
TGF	O
-	O
beta1	O
and	O
kidneys	O
in	O
Alb	O
/	O
TGF	O
-	O
beta1	O
-	O
transgenic	O
mice	O
were	O
analyzed	O
for	O
WT1	O
expression	O
.	O


RESULTS	O
:	O
In	O
cultured	O
podocytes	O
,	O
TGF	O
-	O
beta1	O
reduced	O
WT1	O
protein	O
expression	O
determined	O
by	O
western	O
blotting	O
beginning	O
at	O
8	O
h	O
and	O
decreased	O
WT1	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
measured	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
beginning	O
at	O
3	O
h	O
.	O


Knockdown	O
of	O
Smad4	O
by	O
small	O
hairpin	O
(	O
sh	O
)	O
RNA	O
partially	O
rescued	O
the	O
TGF	O
-	O
beta1	O
-	O
induced	O
reduction	O
of	O
both	O
WT1	O
protein	O
and	O
mRNA	O
expressions	O
in	O
the	O
cultured	O
podocytes	O
.	O


TGF	O
-	O
beta1	O
did	O
not	O
alter	O
luciferase	O
activity	O
of	O
the	O
reporter	O
construct	O
for	O
a	O
human	O
WT1	O
promoter	O
but	O
reduced	O
that	O
for	O
a	O
human	O
WT1	O
5	O
'	O
enhancer	O
construct	O
,	O
suggesting	O
that	O
TGF	O
-	O
beta1	O
may	O
regulate	O
WT1	O
expression	O
by	O
altering	O
the	O
5	O
'	O
enhancer	O
activity	O
.	O


In	O
the	O
transgenic	O
mice	O
,	O
WT1	O
protein	O
expression	O
in	O
podocytes	O
was	O
decreased	O
at	O
1	O
and	O
3	O
weeks	O
of	O
age	O
,	O
while	O
glomeruloclerosis	S-DISEASE
developed	O
after	O
3	O
weeks	O
.	O


CONCLUSION	O
:	O
TGF	O
-	O
beta1	O
reduces	O
WT1	O
expression	O
in	O
cultured	O
human	O
podocytes	O
and	O
podocytes	O
in	O
mice	O
before	O
overt	O
glomerulosclerosis	S-DISEASE
begins	O
.	O


The	O
effects	O
are	O
at	O
least	O
partially	O
Smad4	O
dependent	O
.	O


Our	O
findings	O
identify	O
a	O
novel	O
pathway	O
linking	O
TGF	O
-	O
beta1	O
to	O
podocyte	B-DISEASE
injury	E-DISEASE
and	O
FSGS	S-DISEASE
.	O


The	O
WT1	O
reduction	O
may	O
be	O
a	O
useful	O
marker	O
for	O
early	O
podocyte	B-DISEASE
injury	E-DISEASE
.	O
